免疫治疗中偶然发现脑膜瘤的体积增长率
本研究回顾性分析25例因各类原发转移癌接受检查点抑制剂(CI)治疗且偶然发现脑膜瘤的患者,比较CI治疗前后的脑膜瘤体积,未发现治疗前后肿瘤体积有显著差异(1.31 ± 0.46 vs. 1.34 ± 0.46,p=0.8)。随访超过1年的13例患者年增长率为0.011 ± 0.011 cm³/年,5例出现轻微体积缩小。作者认为CI可能影响脑膜瘤自然史,需进一步研究明确潜在临床指征和治疗目标。
要点
- 25例接受CI治疗的患者中,治疗前后脑膜瘤体积无显著差异(p=0.8)。
- 随访超过1年的13例患者年增长率为0.011 ± 0.011 cm³/年。
- 5例患者出现轻微体积缩小,缩小量为0.12 ± 0.10 cm³(较基线21 ± 6%)。
核心结论
- 检查点抑制剂可能影响脑膜瘤的自然史,需进一步研究明确潜在临床指征和治疗目标。
研究设计与样本
- 回顾性研究,利用纽约大学Perlmutter癌症中心数据平台筛选因各类癌症接受检查点抑制剂治疗且具有连续头颅CT或MRI脑膜瘤报告的患者,排除同期接受化疗者。
- 共纳入25例患者,其中14例(56%)因黑色素瘤接受CI,5例(20%)因非小细胞肺癌等接受CI。
主要发现
- CI治疗前后脑膜瘤体积无显著差异(1.31 ± 0.46 vs. 1.34 ± 0.46,p=0.8)。
- 随访超过1年的13例患者年增长率为0.011 ± 0.011 cm³/年。
- 5例患者出现轻微体积缩小,缩小量为0.12 ± 0.10 cm³(较基线21 ± 6%)。
- 未发现肿瘤体积缩小的显著预测因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The expression of PD-L1 in high-grade meningiomas made it a potential target for immunotherapy research in refractory cases. Several prospective studies in this field are still on going. We sought to retrospectively investigate the effects of check-point inhibitors (CI) on meningiomas that had been naïve to either surgical or radiation approaches by following incidental meningiomas found during treatment with CI for various primary metastatic cancers. METHODS: We used the NYU Perlmutter Cancer Center Data Hub to find patients treated by CI for various cancers, who also had serial computerized-tomography (CT) or magnetic-resonance imaging (MRI) reports of intracranial meningiomas. Meningioma volumetric measurements were compared between the beginning and end of the CI treatment period. Patients treated with chemotherapy during this period were excluded. RESULTS: Twenty-five patients were included in our study, of which 14 (56%) were on CI for melanoma, 5 (20%) for non-small-cell lung cancer and others. CI therapies included nivolumab (n = 15, 60%), ipilimumab (n = 11, 44%) and pembrolizumab (n = 9, %36), while 9 (36%) were on ipilimumab/nivolumab combination. We did not find any significant difference between tumor volumes before and after treatment with CI (1.31 ± 0.46 vs. 1.34 ± 0.46, p=0.8, respectively). Among patients beyond 1 year of follow-up (n = 13), annual growth was 0.011 ± 0.011 cm3/year. Five patients showed minor volume reduction of 0.12 ± 0.10 cm3 (21 ± 6% from baseline). We did not find significant predictors of tumor volume reduction. CONCLUSION: Check-point inhibitors may impact the natural history of meningiomas. Additional research is needed to define potential clinical indications and treatment goals.
引用
- Berger A, Mullen R, Bernstein K, et al. Volumetric growth rate of incidentally found meningiomas on immunotherapy. J Neurooncol. 2024. PMID: 38194196. doi:10.1007/s11060-023-04558-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。